SCHEMBL3770291

SCHEMBL3770291

Cc1nc(-c2ccc(C(F)(F)F)cc2)sc1C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
CHRM4 P08173 1/20 0.47
CNR1 P21554 1/20 0.43
HRH3 Q9Y5N1 2/20 0.41
PPARA Q07869 6/20 0.41
PPARD Q03181 3/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
MAPT P10636 1/20 0.40
CRHBP P24387 1/20 0.40
KMT2A Q03164 1/20 0.40
CRHR2 Q13324 1/20 0.40
OXTR P30559 1/20 0.40
THRA P10827 2/20 0.40
THRB P10828 2/20 0.40
PPARG P37231 2/20 0.39
SCN5A Q14524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405561 0.90 ALDH1A1 (0.53) NPC1ALDH1A1GAACHRM4CNR1
SCHEMBL3401794 0.84 NPC1 (0.52) NPC1ALDH1A1GAACHRM4CNR1
SCHEMBL3404901 0.81 SCN5A (0.58) NPC1ALDH1A1GAACNR1HRH3
SCHEMBL3398944 0.81 ALDH1A1 (0.45) NPC1ALDH1A1GAACHRM4CNR1
SCHEMBL3400395 0.79 CNR1 (0.52) ALDH1A1CNR1HRH3PPARAPPARD
SCHEMBL3404145 0.79 ALDH1A1 (0.60) NPC1ALDH1A1CNR1PPARAMEN1
SCHEMBL3767394 0.79 HRH3 (0.56) ALDH1A1GAAHRH3KDM4EMEN1
SCHEMBL3403718 0.79 CNR1 (0.54) ALDH1A1GAACNR1HRH3KDM4E
SCHEMBL3403938 0.79 CNR1 (0.51) ALDH1A1GAACNR1HRH3KDM4E
SCHEMBL3402224 0.78 HRH3 (0.48) ALDH1A1GAACNR1HRH3PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 NPC1 3462/4885ALDH1A1 1210/4885GAA 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.